INTRODUCTION
Invasive fungal diseases (IFD) are a major cause of mortality in acute leukemia (AL), affecting approximately 5-15% of acute myeloid leukemia (AML) patients (1, 2) . The mortality of patients with IFD at 3 months of diagnosis is reported to be between 28%-42% in invasive aspergillosis and 23%-40% in invasive candidiasis (3) (4) (5) (6) (7) (8) . When the patients survive to IFD, completing the full chemotherapy schedule may be difficult because of the risk of fungal relapse estimated around 30% (9) , and most hematologists give a secondary prophylaxis (9, 10) , as supported by international guidelines (11) (12) . Additionally, they often delay or reduce the doses of chemotherapy, at least until achieving a stable condition of the IFD.
Any change in a chemotherapy protocol -delaying the courses, reducing the doses, or changing the drugs -may impact on the prognosis of AL patients (13, 14) . Despite large data on the mortality rates of IFD in hematology patients, no study looked at the impact of the occurrence of an IFD on the application of the AL chemotherapy regimen initially planned in patients who survived to IFD.
The objectives of this study were to assess the impact of IFD on the application of chemotherapy regimens in patients with AL and surviving to IFD, and the possible impact of these changes on the event-free (EFS) and overall survival (OS).
DESIGN AND METHODS
This is a single-center, hospital-based case-control study on patients consecutively treated for AL between 2000 and 2008, in our department. The study was approved by the Comité de Protection des Personnes -Ile de France IX.
All AL patients <60 years were housed in laminar-air flow (LAF) rooms during the chemotherapy courses with an expected neutropenia >10 days. The older patients (> 60 y) were hospitalized in regular single rooms unless a LAF room was available. All AL patients received oral non-absorbable polyens, without other antifungal prophylaxis, and were screened twice weekly by galactomannan antigenemia in blood.; IFD were classified according to the EORTC-MSG criteria (15) . All chemotherapy regimens, and any change in the schedule, were individually discussed within the staff. The department is involved in the Acute Promyelocytic Group (APL) (16) , in the Acute Leukemia French Association (ALFA) for other AML (17, 18) , and in the national acute lymphoblastic leukemia (ALL) group (19, 20) . All patients were treated with regimens defined in a written procedure, whatever the patient was, or was not, included in a prospective study.
The case patients were male or females aged >15 years, treated for AL, who had a probable or proven IFD, were treated in, or according to, a given protocol of chemotherapy, survived at least 4 weeks after the IFD diagnosis, and were not transplanted, either because they had no indication of hematopoietic cell A delay in the chemotherapy regimen was defined by a chemotherapy starting after the maximal period allowed in the protocol. A change of chemotherapy regimen was defined by any dose reduction, cytotoxic switch, change of timing, or switch to a palliative treatment justified in the chart by the severity of the IFD. Quantitative variables are expressed as median (range) and qualitative variables as number (%). Odds ratios (OR) with their 95% confidence intervals (CI) were estimated separately for each parameter using unconditional logistic regression.
Survival assessment was censored at 30 months after inclusion.
The EFS was defined as survival without leukemia relapse or fungal death.
To analyse the impact of IFD on EFS and OS, time from beginning of the last course of chemotherapy to event of patients with no, probable or proven IFD was estimated using Kaplan-Meier method and compared using logrank analysis. Hazard ratios and their 95% CI were estimated using Cox proportional hazard models. 
RESULTS AND DISCUSSION
During the study period, 362 new cases of AL and 151 relapses were cared in our department. Sixty-nine patients (13.4%) developed a first proven or probable IFD.
Among the 64 patients who survived 4 weeks later, 24 received an allogeneic HCT within 3 months, 5 experienced IFD during the last planned course of chemotherapy, The administration of the next chemotherapy course was delayed in 16 cases (57,1%) and in 16 control subjects (20,5%) (p=.001). In patients whose treatment was delayed, this delay was of a median of 11 days (1-38 days) in the case group, and of 4.5 days (1-45 days) in the control group (p=0.0058). The chemotherapy protocol was changed in 8 cases (28, 6%) and 6 control subjects (7, 7%) (p =. 009).
The protocol changes were: (1) an early switch to a maintenance treatment for 4 cases (14,3%) and no control subject, (2) a switch to a palliative treatment for 2 cases (7,1%) and 2 control subjects (2,6%), (3) a dose-reduction of chemotherapy in 1 case (3,6%) and 2 control subjects (2,56%), (4) a switch to an outpatient management for 1 control subject (1,3%), and (5) . The probability of EFS was also significantly worst in the older patients, in patients with hyperleucocytosis, poor prognosis cytogenetics, and in patients with AML6 or secondary leukemia ( Figure 1 and Table   2 ). Similar results were observed for OS. The changes or delays in chemotherapy had no significant impact on OS and EFS. In the multivariate analysis, a proven IFD remained significantly associated with a poor prognosis after adjusting for the parameters which negatively influenced the survival (older age, WBC count at diagnosis, cytogenetics, and type of leukemia).
Our study shows that despite an initial favourable outcome, the occurrence of IFD during AL treatment led us to change the chemotherapy program, either by delaying the next course, changing the drug, or reducing the doses. Second, the EFS and OS of AL patients was negatively influenced by the occurrence of a proven IFD, although this does not seem to be significantly related to the chemotherapy changes, maybe due to the low number of proven IFD in our study. Also, the fact that 86% of the IFD patients received secondary antifungal prophylaxis may have minimized the risk of fungal reactivation. Our study has several limits. First, we did not include patients with possible IFD. The reason is the uncertainties of fungal diagnosis in this group. The fact that survival in our patients was significantly lower in the proven subgroups when compared to the non-IFD group or to the probable IFD group, suggests that the more the level of proof of the IFD, the more impact on survival, as recently shown in HCT patients (21) . Also, the criteria for probable aspergillosis, mostly based on galactomannan antigen and imaging, may select some patients who finally have no IFD (15) . Second, we excluded patients who underwent an allogeneic HCT after the IFD episode. As our policy was to favour HCT each time indicated by the characteristics of the disease, these patients are not comparable to the chemotherapy patients. Moreover, there are already large data on such patients in the literature (22) . Third, we did not include the rare patients who died early during induction, from or with IFD, for whom the impact of IFD is obvious. The 3-months mortality rate of IFD is widely illustrated in the literature (1, 2, 4) . On the other hand, there was so far no data on the outcome of patients getting IFD, surviving to IFD, and needing ongoing chemotherapy.
Our study shows that in case of IFD during the course of AL therapy, despite initial survival, this event impacts on the chemotherapy regimen, and on OS and EFS at least for proven IFD. In order to decrease this impact of IFD in AL patients, several ways may be combined: primary prophylaxis, environmental measures (26-28), empirical or pre-emptive antifungal treatment (23, 24) ; and secondary prophylaxis..
However, the best should be done not to change the chemotherapy regimen, which may impair the overall prognosis. 
